Sinovac Biotech, Ltd. financial statements, including revenue, expenses, profit, and loss

The total revenue of SVA for the last semiannual is 307.87 M USD, and it's 119.27% higher compared to the previous semiannual. The net income of H2 23 is -116.84 M USD.